REVANCE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.66 USD | +0.55% |
|
-3.94% | -58.36% |
Financials (USD)
| Sales 2024 * | 282M | Sales 2025 * | 386M | Capitalization | 379M |
|---|---|---|---|---|---|
| Net income 2024 * | -185M | Net income 2025 * | -89M | EV / Sales 2024 * | 2.44 x |
| Net Debt 2024 * | 309M | Net Debt 2025 * | 230M | EV / Sales 2025 * | 1.58 x |
| P/E ratio 2024 * |
-1.76
x | P/E ratio 2025 * |
-3.44
x | Employees | 597 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.53% |
More Fundamentals
* Assessed data
More news
Latest transcript on Revance Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.55% | ||
| 1 week | -3.94% | ||
| Current month | -25.61% | ||
| 1 month | -21.29% | ||
| 3 months | -39.30% | ||
| 6 months | -56.38% | ||
| Current year | -58.36% |
1 week
3.61
3.90
1 month
3.615.03
Current year
3.619.75
1 year
3.6137.98
3 years
3.6137.98
5 years
3.6137.98
10 years
3.6142.41
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 18-11-04 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 11-02-28 |
Mark Foley
CEO | Chief Executive Officer | 58 | 17-09-04 |
Jill Beraud
BRD | Director/Board Member | 63 | 19-06-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.18% | 0 M€ | 0.00% | - | |
| 0.14% | 0 M€ | 0.00% | - | |
| 0.06% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 3.64 | -3.70% | 1,812,785 |
| 24-04-19 | 3.78 | -0.26% | 1,647,559 |
| 24-04-18 | 3.79 | +0.80% | 1,598,010 |
| 24-04-17 | 3.76 | -1.31% | 1,740,205 |
| 24-04-16 | 3.81 | -4.03% | 2,419,418 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
3.64
USD
Average target price
16.33
USD
Spread / Average Target
+348.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.36% | 379M | |
| -1.44% | 85.68B | |
| +4.08% | 41.4B | |
| -25.35% | 28.22B | |
| +54.31% | 24.64B | |
| -4.52% | 16.98B | |
| -42.09% | 13.29B | |
| -17.77% | 11.66B | |
| -12.10% | 11.65B | |
| +0.75% | 8.18B |
- Stock Market
- Equities
- RVNC Stock
